HOPO Therapeutics awarded BARDA contract of up to $226 million
The Biomedical Advanced Research and Development Authority (BARDA) has awarded HOPO Therapeutics an R&D contract of up to $226 million to advance the company’s oral decorporation agent HOPO-101 through registrational studies. This partnership with BARDA aims to progress HOPO-101 to FDA approval as a medical countermeasure to treat exposure to radioactive actinide elements, as well as other forms of heavy metal toxicity.